DICE

References

• Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10:26 - 35; http://dx.doi.org/10.1038/sj.cdd.4401186; PMID: 12655293
   PubMed Web of Science ®Google Scholar
• Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33:29 - 55; http://dx.doi.org/10.1146/annurev.genet.33.1.29; PMID: 10690403
   PubMed Web of Science ®Google Scholar
• Peter ME, Barnhart BC, Algeciras-Schimnich A. The Cytokine Handbook: CD95L/FasL and its receptor CD95 (APO-1/Fas). The Cytokine Handbook 2003; 2:885 - 911; http://dx.doi.org/10.1016/B978-012689663-3/50042-9
   Google Scholar
• Rieux-Laucat F, Blachère S, Danielan S, De Villartay JP, Oleastro M, Solary E, Bader-Meunier B, Arkwright P, Pondaré C, Bernaudin F, et al. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 1999; 94:2575 - 82; PMID: 10515860
   PubMed Web of Science ®Google Scholar
• Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996; 335:1643 - 9; http://dx.doi.org/10.1056/NEJM199611283352204; PMID: 8929361
   PubMed Web of Science ®Google Scholar
• Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, Jackson CE, Puck JM, Dale J, Straus SE, et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci U S A 1999; 96:4552 - 7; http://dx.doi.org/10.1073/pnas.96.8.4552; PMID: 10200300
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268:1347 - 9; http://dx.doi.org/10.1126/science.7539157; PMID: 7539157
   PubMed Web of Science ®Google Scholar
• Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, Rösen-Wolff A, Peters AM, Sneller MC, Hallahan CW, Wang J, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98:194 - 200; http://dx.doi.org/10.1182/blood.V98.1.194; PMID: 11418480
   PubMed Web of Science ®Google Scholar
• Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997; 4:32 - 40; http://dx.doi.org/10.1097/00062752-199704010-00006; PMID: 9050377
   PubMedGoogle Scholar
• Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL, Peter ME. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A 2003; 100:11445 - 50; http://dx.doi.org/10.1073/pnas.2034995100; PMID: 14504390
   PubMed Web of Science ®Google Scholar
• Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129:447 - 50; http://dx.doi.org/10.1016/j.cell.2007.04.031; PMID: 17482535
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14:53 - 66; http://dx.doi.org/10.1016/S1359-6101(02)00072-2; PMID: 12485619
   PubMed Web of Science ®Google Scholar
• Martin-Villalba A, Llorens-Bobadilla E, Wollny D. CD95 in cancer: tool or target?. Trends Mol Med 2013; 19:329 - 35; http://dx.doi.org/10.1016/j.molmed.2013.03.002; PMID: 23540716
   PubMed Web of Science ®Google Scholar
• Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, et al. CD95 promotes tumour growth. Nature 2010; 465:492 - 6; http://dx.doi.org/10.1038/nature09075; PMID: 20505730
   PubMed Web of Science ®Google Scholar
• Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6:920 - 3; http://dx.doi.org/10.1038/78688; PMID: 10932231
   PubMed Web of Science ®Google Scholar
• Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5:118 - 25; http://dx.doi.org/10.1038/ncb916; PMID: 12545171
   PubMed Web of Science ®Google Scholar
• Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, Schreglmann N, Martinez A, del Rio JA, Soriano E, Vodrazka P, et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 2006; 13:31 - 40; http://dx.doi.org/10.1038/sj.cdd.4401720; PMID: 16003386
   PubMed Web of Science ®Google Scholar
• Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E, Koch P, Teodorczyk M, Kleber S, Klussmann S, et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009; 5:178 - 90; http://dx.doi.org/10.1016/j.stem.2009.05.004; PMID: 19664992
   PubMed Web of Science ®Google Scholar
• Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003; 8:151 - 60; http://dx.doi.org/10.1023/A:1022918625509; PMID: 12766475
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182:3801 - 8; http://dx.doi.org/10.4049/jimmunol.0801548; PMID: 19265159
   PubMed Web of Science ®Google Scholar
• Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, Raats DA, Sprick MR, Schaefer U, Van Houdt WJ, et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010; 138:2357 - 67; http://dx.doi.org/10.1053/j.gastro.2010.02.046; PMID: 20188103
   PubMed Web of Science ®Google Scholar
• Nijkamp MW, Hoogwater FJ, Steller EJ, Westendorp BF, van der Meulen TA, Leenders MW, Borel Rinkes IH, Kranenburg O. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J Hepatol 2010; 53:1069 - 77; http://dx.doi.org/10.1016/j.jhep.2010.04.040; PMID: 20832890
   PubMed Web of Science ®Google Scholar
• Park SM, Chen L, Zhang M, Ashton-Rickardt P, Turner JR, Peter ME. CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflamm Bowel Dis 2010; 16:1063 - 70; http://dx.doi.org/10.1002/ibd.21195; PMID: 20049944
   PubMed Web of Science ®Google Scholar
• Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E, Ste Marie R, Wang TC, Lyle S, Kurt-Jones E, et al. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology 2009; 137:934 - 44, e1-4; http://dx.doi.org/10.1053/j.gastro.2009.06.004; PMID: 19524576
   PubMed Web of Science ®Google Scholar
• Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, Shi M, Wang Z, Jiang B. Glycogen synthase kinase-3 beta regulates Snail and β-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 2013; 49:2734 - 46; http://dx.doi.org/10.1016/j.ejca.2013.03.014; PMID: 23582741
   PubMed Web of Science ®Google Scholar
• Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, Li WJ, Peng L, Zhang Y, Wang ZQ, Wang J, et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 2013; 32:1183 - 92; http://dx.doi.org/10.1038/onc.2012.126; PMID: 22508480
   PubMed Web of Science ®Google Scholar
• Yuan K, Jing G, Chen J, Liu H, Zhang K, Li Y, Wu H, McDonald JM, Chen Y. Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). J Biol Chem 2011; 286:24776 - 84; http://dx.doi.org/10.1074/jbc.M110.202804; PMID: 21613217
   PubMed Web of Science ®Google Scholar
• Trauzold A, Röder C, Sipos B, Karsten K, Arlt A, Jiang P, Martin-Subero JI, Siegmund D, Müerköster S, Pagerols-Raluy L, et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 2005; 19:620 - 2; PMID: 15670977
   PubMed Web of Science ®Google Scholar
• Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008; 13:235 - 48; http://dx.doi.org/10.1016/j.ccr.2008.02.003; PMID: 18328427
   PubMed Web of Science ®Google Scholar
• Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23:3175 - 85; http://dx.doi.org/10.1038/sj.emboj.7600325; PMID: 15272306
   PubMed Web of Science ®Google Scholar
• Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, et al. Death induced by CD95 or CD95 ligand elimination. Cell Rep 2014; In press http://dx.doi.org/10.1016/j.celrep.2014.02.035; PMID: 24656822
   PubMed Web of Science ®Google Scholar
• Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30:180 - 92; http://dx.doi.org/10.1016/j.immuni.2009.01.001; PMID: 19239902
   PubMed Web of Science ®Google Scholar
• Shrestha B, Diamond MS. Fas ligand interactions contribute to CD8+ T-cell-mediated control of West Nile virus infection in the central nervous system. J Virol 2007; 81:11749 - 57; http://dx.doi.org/10.1128/JVI.01136-07; PMID: 17804505
   PubMed Web of Science ®Google Scholar
• Tirosh R, Berke G. T-Lymphocyte-mediated cytolysis as an excitatory process of the target. I. Evidence that the target cell may be the site of Ca2+ action. Cell Immunol 1985; 95:113 - 23; http://dx.doi.org/10.1016/0008-8749(85)90300-4; PMID: 3928177
   PubMed Web of Science ®Google Scholar
• Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369:31 - 7; http://dx.doi.org/10.1038/369031a0; PMID: 8164737
   PubMed Web of Science ®Google Scholar
• MacLennan IC, Gotch FM, Golstein P. Limited specific T-cell mediated cytolysis in the absence of extracellular Ca2+. Immunology 1980; 39:109 - 17; PMID: 6769782
   PubMed Web of Science ®Google Scholar
• Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177:195 - 200; http://dx.doi.org/10.1084/jem.177.1.195; PMID: 7678113
   PubMed Web of Science ®Google Scholar
• Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370:650 - 2; http://dx.doi.org/10.1038/370650a0; PMID: 7520535
   PubMed Web of Science ®Google Scholar
• Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528 - 30; http://dx.doi.org/10.1126/science.7518614; PMID: 7518614
   PubMed Web of Science ®Google Scholar
• Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994; 1:357 - 64; http://dx.doi.org/10.1016/1074-7613(94)90066-3; PMID: 7533644
   PubMed Web of Science ®Google Scholar
• Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002; 168:3484 - 92; PMID: 11907109
   PubMed Web of Science ®Google Scholar
• Shimizu M, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells. Cancer Immunol Immunother 1998; 47:143 - 8; http://dx.doi.org/10.1007/s002620050514; PMID: 9829839
   PubMed Web of Science ®Google Scholar
• Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 2003; 171:2402 - 12; PMID: 12928387
   PubMed Web of Science ®Google Scholar
• Dobrzanski MJ, Reome JB, Hollenbaugh JA, Hylind JC, Dutton RW. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res 2004; 64:406 - 14; http://dx.doi.org/10.1158/0008-5472.CAN-03-2580; PMID: 14729652
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170:6338 - 47; PMID: 12794167
   PubMed Web of Science ®Google Scholar
• Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183:657 - 61; http://dx.doi.org/10.1084/jem.183.2.657; PMID: 8627178
   PubMed Web of Science ®Google Scholar
• Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999; 163:4462 - 72; PMID: 10510388
   PubMed Web of Science ®Google Scholar
• Lee SH, Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Cancer Gene Ther 2004; 11:237 - 48; http://dx.doi.org/10.1038/sj.cgt.7700678; PMID: 14739939
   PubMed Web of Science ®Google Scholar
• Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63:4095 - 100; PMID: 12874012
   PubMed Web of Science ®Google Scholar
• Böhm W, Thoma S, Leithäuser F, Möller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161:897 - 908; PMID: 9670968
   PubMed Web of Science ®Google Scholar
• Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW, Wiltrout TA, Nagashima K, Back TC, Wiltrout RH. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108:51 - 62; http://dx.doi.org/10.1172/JCI200110128; PMID: 11435457
   PubMed Web of Science ®Google Scholar
• Kowalczyk DW, Wlazlo AP, Giles-Davis W, Kammer AR, Mukhopadhyay S, Ertl HC. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther 2003; 10:870 - 8; http://dx.doi.org/10.1038/sj.cgt.7700653; PMID: 14712313
   PubMed Web of Science ®Google Scholar
• Barth RJ Jr., Mulé JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173:647 - 58; http://dx.doi.org/10.1084/jem.173.3.647; PMID: 1900079
   PubMed Web of Science ®Google Scholar
• Prévost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000; 164:3645 - 51; PMID: 10725721
   PubMed Web of Science ®Google Scholar
• Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 2004; 173:1738 - 43; PMID: 15265903
   PubMed Web of Science ®Google Scholar
• Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152:1127 - 33; PMID: 7507960
   PubMed Web of Science ®Google Scholar
• Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci U S A 1994; 91:4185 - 9; http://dx.doi.org/10.1073/pnas.91.10.4185; PMID: 7514297
   PubMed Web of Science ®Google Scholar
• Listopad JJ, Kammertoens T, Anders K, Silkenstedt B, Willimsky G, Schmidt K, Kuehl AA, Loddenkemper C, Blankenstein T. Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A 2013; 110:2276 - 81; http://dx.doi.org/10.1073/pnas.1218295110; PMID: 23341634
   PubMed Web of Science ®Google Scholar
• Trauth BC, Klas C, Peters AM, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301 - 5; http://dx.doi.org/10.1126/science.2787530; PMID: 2787530
   PubMed Web of Science ®Google Scholar
• Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747 - 56; http://dx.doi.org/10.1084/jem.169.5.1747; PMID: 2469768
   PubMed Web of Science ®Google Scholar
• Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806 - 9; http://dx.doi.org/10.1038/364806a0; PMID: 7689176
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11:4642 - 9; http://dx.doi.org/10.4161/cc.22937; PMID: 23187803
   PubMed Web of Science ®Google Scholar
• Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, Nagata S. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11:294 - 300; http://dx.doi.org/10.1038/ng1195-294; PMID: 7581453
   PubMed Web of Science ®Google Scholar
• Karray S, Kress C, Cuvellier S, Hue-Beauvais C, Damotte D, Babinet C, Lévi-Strauss M. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004; 172:2118 - 25; PMID: 14764677
   PubMed Web of Science ®Google Scholar
• Senju S, Negishi I, Motoyama N, Wang F, Nakayama K, Nakayama K, Lucas PJ, Hatakeyama S, Zhang Q, Yonehara S, et al. Functional significance of the Fas molecule in naive lymphocytes. Int Immunol 1996; 8:423 - 31; http://dx.doi.org/10.1093/intimm/8.3.423; PMID: 8671629
   PubMed Web of Science ®Google Scholar
• Hao Z, Hampel B, Yagita H, Rajewsky K. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J Exp Med 2004; 199:1355 - 65; http://dx.doi.org/10.1084/jem.20032196; PMID: 15148335
   PubMed Web of Science ®Google Scholar
• Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities?. Biochim Biophys Acta 2005; 1755:25 - 36; PMID: 15907590
   PubMed Web of Science ®Google Scholar
• Eck MJ, Manley PW. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr Opin Cell Biol 2009; 21:288 - 95; http://dx.doi.org/10.1016/j.ceb.2009.01.014; PMID: 19217274
   PubMed Web of Science ®Google Scholar
• Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11:873 - 86; http://dx.doi.org/10.1038/nrd3847; PMID: 23060265
   PubMed Web of Science ®Google Scholar